Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects by Adelzon A Paula et al.
Paula et al. AIDS Research and Therapy 2013, 10:32
http://www.aidsrestherapy.com/content/10/1/32REVIEW Open AccessMetabolic syndrome in HIV-infected individuals:
underlying mechanisms and epidemiological
aspects
Adelzon A Paula, Melissa CN Falcão and Antonio G Pacheco*Abstract
The success of highly active antiretroviral therapy (HAART) has determined a dramatic decline in AIDS- and
immunodeficiency-related causes of death in the HIV-infected population. As life-expectancy increases, such individuals
have become gradually exposed not only to the effects of aging itself, but also to the influence of environmental risk
factors, which are known to act in the general population. These features can lead to obesity, diabetes mellitus and
ultimately cardiovascular diseases (CVD). Metabolic complications and abnormal fat distribution were frequently
observed after a few years of antiretroviral therapy and, as the array of antiretroviral drugs became broader, long term
metabolic alterations are becoming far more common worldwide. Nevertheless, the risk of not being on HAART
is overwhelmingly greater than the metabolic adverse events in terms of morbidity and mortality events. HIV/
HAART-induced metabolic unbalances overlap in some extent the components of Metabolic Syndrome (MetS) and
its high rates in the HIV population place infected individuals in an elevated CVD risk category. MetS can explain at
least in part the emergence of CVD as the major morbidity and mortality conditions in the HIV population. In this
review we convey information on the underlying aspects of MetS during HIV infection, highlighting some
physiopathological and epidemiological features of this comorbidity along with the role played by HIV itself and
the synergy action of some antiretroviral drugs. Considerations on MetS management in the HIV population are
also depicted.
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Introduction
The introduction and widespread use of highly active anti-
retroviral therapy (HAART) in the mid 1990’s, has led
HIV-infected individuals to experience a dramatic decline
in immunodeficiency-related events, including causes of
death [1-3]. As a consequence, life-expectancy increased,
which exposed them to the effects of aging itself, including
the influence of the same environmental risk factors
known to act in the general population and contributing
to the occurrence of obesity, diabetes mellitus (DM), and
cardiovascular diseases (CVD) [4,5].
Metabolic syndrome (MetS) has been playing a major
role as a marker for metabolic disorders [6]. According to
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stated.Survey, prevalence of MetS in the general US population
has been estimated in 25% and this number has been
growing continuously over time [7]. A recent British study
on a cohort of middle-aged men reported the prevalence
of MetS at 26% [8]. The increasing prevalence of MetS re-
lates to the growing tendencies verified for its underlying
causes, such as unbalanced food intake, physical inactivity
and obesity, which peaked in the developed world and
have been suggested to be independent risk factors for the
development of the syndrome [8].
MetS encompasses a cluster of risk factors leading to
CVD as primary clinical outcome and contribute to higher
risks of DM. Such factors include obesity (mainly central
adiposity), defective glucose metabolism (DM, impaired
glucose tolerance, or impaired fasting glycaemia), raised
blood pressure, and elevated TG and low HDL-c levels.
Notwithstanding the cardiovascular outcomes, individuals
with MetS are thought to be more susceptible to a rangeal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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syndrome [10] and asthma [11].
Since its first comprehensive recognition in 1988, when
Reaven described the relation between insulin resistance,
plasma insulin levels, glucose intolerance and hyperten-
sion [12], MetS has been subject to a number of oper-
ational definitions. Despite the absence of a consensual
definition to date, which dampers accurate prevalence es-
timates, the different working definitions for the syndrome
converge to some extent. Four of the main MetS oper-
ational definitions and their differential and overlapping
components can be seen in Table 1.
MetS in HIV infection
Despite the unquestionable success of HAART, prevalence
of DM, insulin resistance, blood pressure fat redistribution
and mainly dyslipidemia have substantially increased after
its global scaling up [17]. Though the actual numbers of
MetS in HIV populations are still debatable, reported prev-
alences for MetS in the HIV population can be regarded as
high, ranging from 11.2% up to 45.4% (Table 2). The high
rates of MetS in the HIV-infected population place it in a
CVD high-risk category, turning MetS into a major public
health concern [18-20].
The natural course of HIV infection is associated with
particular unbalances in lipid levels. The dynamics of HIV
infection determine an initial decrease in HDL-c followed
by a decrease in LDL-c levels. In more advanced stages,
there is an increase in TG and in VLDL-c levels with a
strong correlation between serum IFN-α levels and TG
clearance time [30]. Notwithstanding, there is evidence for
different MetS pathways among HIV individuals under
HAART treatment, since a recent report indicated an un-
balanced relationship between HDL-c and TG in the pres-
ence of high TG levels or another component of MetS
[31], which claims for an appropriate MetS definition in
HIV infection.
Physiopathology of MetS in HIV-infected individuals
Since the description of abnormal fat distribution follow-
ing a few years on HAART with Protease Inhibitors (PI),
chiefly ritonavir plus saquinavir combination [32], meta-
bolic changes in HIV individuals have been widely studied.
The main features included dyslipidemia, insulin resist-
ance, and lipodystrophy. Many of these phenotypic and
metabolic changes fit MetS criteria [18] and therefore,
there is growing concern that metabolic complications as-
sociated to HIV and HAART may lead to increased risk
for cardiovascular events. Such reasoning can explain, at
least partially, the emergence of CVD as causes of morbid-
ity and death in the HIV population.
HIV infection is associated with deregulated inflamma-
tory response, through suppressing genes necessary to
extinguish inflammation. In such context, HIV-infectedmonocytic cells have downregulated expression of the tyro-
sine kinase RON, a negative regulator of the inflammatory
process and HIV transcription as well, via ubiquitin-
proteosome degradation [33]. This long term inflammatory
environment along with higher white blood cells count act
as a metabolic risk factor in the pathogenesis of HIV [34].
While obesity is a central component of MetS, adipose
tissue is a dynamic source of several proinflammatory cy-
tokines, chemokines, growth factors and complement pro-
teins, which can alter endothelial cells integrity and
contribute to the atherosclerosic process [35]. This consti-
tutive low-grade inflammatory status is characterized by
increased plasma levels of TNF-α and IL-6 and other me-
diators of inflammation [36]. The interplay between HIV-
triggered low-grade inflammatory injury, inbalances in
lipid and glucose metabolism, and fat redistribution has
already been described, with soluble urokinase plasmino-
gen activator receptor (suPAR) emerging as a stronger
predictor of dysmetabolism than TNF-α and IL-6 [37].
Insulin resistance is thought to determine excessive adi-
pokine production yielding to endothelial dysfunction. As
it progresses towards MetS and DM, the ongoing process
of endothelial damage, along with inflammation, throm-
bosis and oxidation orchestrate at the vessel wall to pro-
duce atherosclerotic plaques [36]. Accordingly, caloric
restriction-induced weight loss contributes to the regula-
tion of a wide variety of inflammation-related molecules
adipose tissue and upregulated the expression of mole-
cules with anti-inflammatory properties [38].
HIV-related risk factors
Inflammation is thought to be a major determinant in
the pathogenesis of both DM and atherosclerosis. How-
ever, the key inflammatory molecules involved in ather-
oma and DM in HIV individuals on HAART are poorly
understood [39]. Epicardial and thoracic periaortic fat
deposition have been associated to high levels of hsCRP,
insulin resistance and subclinical atherosclerosis in viro-
logically suppressed HIV-infected patients on HAART
and both have been related to MetS [40,41]. In fact, epi-
cardial fat storage and some lipodystrophy phenotypes
and well established risk factors for atherosclerosis seem
to be associated [42].
A case–control study performed among HIV-infected
ART-naïve Africans showed a high prevalence of MetS and
increased arterial stiffness, considered an early marker of
atherosclerosis. In this report, prevalence of impaired fast-
ing glucose and DM, levels of fasting TG and the athero-
genic dyslipidemia ratio were higher in HIV-individuals
than in controls. Elevated blood pressure prevalence was
high but comparable in both groups [43].
Although to a lesser degree than HAART, HIV infection
act as an independent risk factor for atherosclerosis devel-
opment and cardiovascular damage, been responsible for
Table 1 Work definitions for MetS
Definition EGIR (1999) [13] NCEP/ATP III (2001) [14] AHA-NHLBI (2005) [15] IDF (2006) [16]
Mandatory criteria
Insulin resistance defined as the top
25% of the fasting insulin values
among nondiabetic individuals
None None Waist circumference# with ethnicity-specific values
Aditional criteria At least two of the following: At least three of the following: At least three of the following: At least two of the following:
Central obesity Waist circumference≥ 94 cm
(male), ≥ 80 cm (female)
Waist circumference≥ 102 cm
or 40 inches (male), ≥ 88 cm
or 35 inches (female)
Waist circumference≥ 102 cm
or 40 inches (male), ≥ 88 cm or
35 inches (female)
See mandatory criteria
Dyslipidemia TG≥ 2.0 mmol/L and/or HDL-C <
1.0 mmol/L or treated for dyslipidemia
TG≥ 1.7 mmol/L (150 mg/dl)
OR HDL-C < 40 mg/dL
(male), < 50 mg/dL (female)
TG≥ 1.7 mmol/L (150 mg/dl)
OR HDL-C < 40 mg/dL (male),
< 50 mg/dL (female)
TG > 150 mg/dL (1.7 mmol/L), or specific treatment for this lipid
abnormality OR HDL-C < 40 mg/dL (1.03 mmol/L) in males,
< 50 mg/dL (1.29 mmol/L) in females, or specific
treatment for this lipid abnormality
Blood pressure ≥ 140/90 mmHg or
antihypertensive medication
≥ 130/85 mmHg or
antihypertensive medication
≥130/85 mmHg Systolic BP > 130 OR diastolic BP >85 mmHg,
or treatment of previously diagnosed hypertension
Glucose metabolism Fasting plasma glucose≥ 6.1 mmol/L Fasting plasma glucose≥
6.1 mmol/L (110 mg/dl)
Fasting plasma
Glucose ≥ 100 mg/dL
Raised fasting plasma glucose: >100 mg/dL
(5.6 mmol/L), or previously diagnosed tDM



















Table 2 MetS prevalences among different HIV populations
MetS criteria Prevalence (%) Remarks Reference/year
NCEP-ATP III 45.4 n = 553, Italy. [21]/2002
On HAART
17 n = 710, Spain. [22]/2005
22 n = 1243 Italy. [23]/2006
SIMONE multicenter study
15.8 n = 146, Spain Madrid. [24]/2006
On HAART, plus 159 HIV negative patients matched by BMI
18 n = 788. [25]/2007
Lipodystrophy case definition cohort (international multicenter)
25.5 n = 471, USA. [26]/2007
NHANES, matched for age, gender, ethnicity, tobacco use
20.8 n = 1243, Italy. [25]/2007
SIMONE multicenter study
EGIR 39.8 n = 201, Italy. [27]/2002
On HAART.
33.1 n = 287, Italy. [28]/2003
On HAART
NHLBI 24 n = 77, USA. [20]/2006
NFHL Study
IDF 14 n = 788. [25]/2007
Lipodystrophy case definition cohort (international multicenter)
11.4 n = 210, Spain. [29]/2007
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pairment [44]. HIV-specific mechanisms include immune
dysfunction and increased inflammatory response leading
to increased thrombosis and changes in lipid levels and
cholesterol metabolism, which are also responsible for
MetS and cardiovascular risk in the general population.
Tat, a key molecule in HIV replication and pathogenesis
can affect both mesenchymal stem cells survival and
differentiation by downregulating the expression of
VEGF-induced endothelial markers and this might play
an instrumental role in vessel damage and in the athero-
sclerotic lesions observed in HIV infection [45].
The pathogenesis of dyslipidemia in HIV-infected in-
dividuals has been associated with increased apolipo-
protein levels, increased hepatic synthesis of VLDL-c,
decreased clearance of TG [46] and also to the effects of
viral infection itself, acute-phase proteins and increase
in circulating cytokines such as IL-6 and IFN-α [47]. In
fact, lipid unbalances are common in art-naïve HIV-
infected individuals even in the absence of major host-
related risk factors for dyslipidemia, such as high blood
pressure, DM and obesity [44].
HIV-1 infection itself is able to elicit adipose tissue al-
terations critical to lipodystrophy causation through adi-
pose tissue gene expression alterations. Subcutaneousadipose tissue from infected individuals bears reduced
mRNA levels of cytochrome c oxidase subunit II com-
pared to non-infected individual. These concentrations
decreased further in association with HAART [48].
Antiretroviral-related risk factors
HAART therapy has both positive and deleterious effects
on cardiovascular risk. Cumulative evidence has pointed
to the relation between different metabolic disorders and
HAART use, including insulin resistance, hyperlipidaemia,
and lipodystrophy [49], even though it remains controver-
sial whether these effects can be directly ascribed to anti-
retroviral drugs [26]. Antiretroviral-driven suppression of
HIV replication seem to act as double-edged sword since
it can reduce and also increase HIV-related cardiovascular
risk through its toxicity [50].
Despite effective treatment with HAART, some degree
of chronic immune activation may persist. In the SMART
trial, participants bearing ≤400 copies/mL of HIV RNA
also had elevated hsCRP and IL-6 levels in 38% and 60%,
respectively, in comparison to normal individuals form co-
horts for cardiovascular outcomes [51]. HIV-infected indi-
viduals have higher blood levels of major inflammation
markers such as IL-6, hsCRP and p-selectin, considered
independently associated with increased cardiovascular
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risk of death by raising IL-6 and D-dimer levels [53].
HAART toxicity depends on the antiretroviral drug
used and may include adverse lipoprotein changes, insu-
lin resistance, inflammation, platelet dysfunction, and
vascular injury. Studies performed in vitro have demon-
strated that some HAART regimens, such as those in-
cluding zidovudine, some NNRTI (e.g. efavirenz) and
indinavir induce toxicity through induction of cardiomyo-
cyte and endothelial cell apoptosis leading to endothelial
dysfunction and vascular damage [54]. Thus, compared to
untreated HIV infection, the net effect of starting anti-
retroviral therapy on cardiovascular disease risk is un-
known as it may increase or decrease the overall risk [55].
Studies suggest that conventional risk factors will play
major role in the development of CVD in HIV patients, as
seen in the general population and such risk factors urge
to be targeted by prevention strategies [56,57].
The unbalances in glucose metabolism depend on the
particular antiretroviral drug in use. Treatments with stav-
udine [58], zidovudine [59,60], lamivudine [59] or didano-
sine [58], as well as indinavir [61,62], or lopinavir/ritonavir
[60], and efavirenz have [63,64] been implicated in insulin
resistance, glucose metabolism changes, and DM. The
pathways underlying such alterations are not always know
but an in vitro essay with PIs and NRTIs showed altered
adipocyte functions and decreased adiponectin, a positive
regulator of insulin sensitivity, due to an increased expres-
sion and secretion of pro-inflammatory cytokines [65]. In
another study, the PI indinavir has been implicated in in-
ducing insulin resistance by acutely blocking transport of
glucose by the insulin-sensitive glucose transporter
GLUT4, a mechanism not found in non-HIV patients with
DM [62].
Dyslipidemia in HIV population can result from both
uncontrolled HIV disease and clinical restoration after
HAART initiation. Individual, demographic and genetic
traits besides the specific side effects of the antiretroviral
combination contribute greatly to the type and degree of
dyslipidemia seen in this population [66]. According to
the D:A:D, a consortium assessing adverse events of anti-
HIV drugs, the risk associated to certain PI’s (indinavir,
lopinavir/ritonavir, abacavir) was consistently lower than
the one calculated to the annual increment in risk associ-
ated to advanced age and current smoking habit [67]. The
use of lopinavir/ritonavir [68], stavudine [63], efavirenz
[69] and nelfinavir, zidovudine/lamivudine and didano-
sine/stavudine [70] have already been reported as causa-
tive of dyslipedemia by at least one of the following
mechanisms (i) increased TG levels, (ii) increased LDL-c
levels, and (iii) increased HDL-c levels.
Aside these specific cardiovascular risks, CVD have been
reported as adverse effect with some ARV drugs, inde-
pendently of metabolic disorders [71,72]. A meta-analysisindicated an increased risk of myocardial infarction in pa-
tients exposed to abacavir (RR 1.92, 95% CI 1.51-2.42),
and an increased risk associated with each additional year
of exposure to indinavir (RR 1.11, 95% CI 1.05-1.17) and
lopinavir (RR 1.22, 95% CI 1.01-1.47) [72]. A prospective
observational study from the D:A:D consortium showed
that combination antiretroviral therapy was independently
associated with a relative increase 0f 1.26 times in the rate
of myocardial infarction per year of exposure during the
first four to six years of use [58]. Despite these minor
metabolic unbalances described for many antiretroviral
drugs, it is important to keep in mind that the morbidity
and mortality risks for HIV patients not on HAART are
much higher than the risks seen with any antiretroviral
drug or combination of drugs.
Targeting MetS risk factors in the HIV population
As aforementioned, the success of HAART implementa-
tion allowed HIV individuals to live longer and as a conse-
quence they can accumulate the same cardiovascular risks
exposure described for the general population, such as high
blood pressure, DM, dyslipidemia, and smoking habit,
which is known to be a more prevalent risk in the HIV in-
fected than in general population [73]. A French nation-
wide cohort of HIV+ adults on HAART showed that nearly
half the patients were overweight or obese at HAART initi-
ation and 20% of the patients gained excessive weight
within 2 years of HAART initiation [58]. Additionally, a
retrospective cross-sectional study reported that, even
though less common than among the general population,
obesity and overweight were more prevalent in comparison
to wasting in the HIV population [74].
In a recent cohort of HIV-infected patients receiving
care in HIV clinics in US, 38.2% of patients were in either
the moderately high-risk or high-risk categories, of whom
77.9% were current or past smokers, 74.2% had high blood
pressure, 71.5% had elevated baseline LDL-c levels, 70.5%
had low HDL-c levels, and 35.8% had MetS [75].
A recent study has suggested an exclusive map for es-
timating the correct risk of cardiovascular disease in
these patients that should include, besides traditional
risk factors, specific factors for HIV patients like viral
factors, immune activation, chronic inflammation and
side effects of antiretroviral therapy [75].
In managing hyperlipidemia, the decision to use lipid-
lowering therapy or to switch antiretroviral therapy regi-
mens should be individualized. Unfortunately, at least
one-fifth of HIV-infected outpatients with high cardiovas-
cular risk who were eligible for pharmacologic treatment
did not received recommended interventions and so treat-
ment goals could not be achieved [75]. Effective manage-
ment of dyslipidemia in HIV individuals is essential to
reduce cardiovascular risk but presents multiple pitfalls
due to interactions between HAART and lipid-lowering
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HIV patients is selecting lipid-lowering agents capable to
work effectively to restore lipid metabolism while main-
taining proper interactions with HAART [77].
Beyond their canonical activity in inhibiting HMG-CoA
reductase, statins might attenuate inflammation associate
to the low-level viremia which can lead to a higher risk of
age-associated non-AIDS morbidity and mortality. In fact,
there is evidence showing that patients who maintained vi-
rologic suppression on effective HAART obtained add-
itional survival benefit from the use of a statin [77].
As for the general population, cigarette smoking is
thought to be the most important cardiovascular risk
factor among HIV patients. More than half of the sub-
jects evaluated in a cross-sectional analysis were current
or past cigarette smokers, and smoking conferred a 2.35
(95% CI = 1.92-2.87) risk for myocardial infarction [78].
Cessation of smoking was more likely to reduce cardio-
vascular risk than either the choice of the ART regimen
or the use of lipid-lowering drugs [79]. When assessing
carotid intima-media thickness as a surrogate marker of
CVD in HIV cohort, only gender, age, BMI, hypertension
and family history of CVD remained as significant fac-
tors associated with thickened carotid intima-media,
suggesting that traditional CVD risk factors may play a
major role in CVD among HIV population [57].
HIV individuals submitted to short-term exercise
training can undergo reductions in the waist-to-hip ratio
and in the amount of visceral fat, and reductions in the
levels of cholesterol, triglyceride, and LDL-c and such
changes may improve some of the adverse metabolic ef-
fects associated to HAART [80]. The assessing of aer-
obic training in improving abdominal fat accumulation
and metabolic disorders in HIV infection revealed that it
reduced visceral fat, lipid disorders, basal blood lactate
and coronary heart disease and may be particularly im-
portant for patients with marked dyslipidemia [81].
Conclusions
The current HAART-modified natural history of HIV in-
fection has practically turned the disease into a manage-
able chronic condition. As such, special attention should
be paid to both imperfect control of HIV replication and
long-term adverse events linked to drugs used in the
therapeutic scheme. Even though the benefits of HAART
use are overwhelmingly greater than possible MetS and
CVD risks, close management of those patients is called
for, especially due to the fact that general population risk
factors now overlap with specific ones in this population,
even though the former are usually more prominent than
the latter.
Thus, MetS in HIV populations ought to be closely
monitored and controlled by programmatic and compre-
hensive public measures. These findings call for anintegrated management strategy, including smoking cessa-
tion policies, diet modification, and regular physical activ-
ity planning. Finally, comprehensive educational measures
are needed and further research is instrumental to assess
the barriers to implement preconized interventions and to
achieving recommended treatment goals that are singular
to the HIV-population.
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